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Abstract
Purpose N3-o-toluyl-ﬂuorouracil (TFU), the prodrug of
5-ﬂuorouracil (5-FU), is the metabolite of N1-acetyl-N3-o-
toluyl-ﬂuorouracil (atoﬂuding). In the present study, we
aimed to evaluate the efﬁcacy of TFU on the inhibition of
human hepatocellular carcinoma cells via sustained release
of 5-FU. The metabolism of TFU underlying the inhibitory
effect was also analyzed.
Methods In vitro assays, inhibition of cell growth by TFU
was evaluated by the 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide method. The levels of TFU
and 5-FU in the cell culture supernatant ﬂuid were mea-
sured by high-performance liquid chromatography
(HPLC). In vivo assays, the efﬁcacy of TFU was evaluated
in a human hepatocellular carcinoma xenograft mice model
after 3 weeks of oral administration. The distributions of
TFU and 5-FU in plasma and homogenate tissues including
liver, lung and tumor were determined by HPLC.
Results N3-o-toluyl-ﬂuorouracil weakly inhibited the
proliferation of SMMC-7721 and PLC/PRF/5 cells in
the absence of liver microsomal enzymes. In contrast, the
inhibition rates were signiﬁcantly increased in the presence
of these enzymes. HPLC results revealed that TFU was
metabolized slowly by liver microsomal enzymes and
therefore the concentration of 5-FU was gradually
increased with a longer retention time in cell culture
supernatant ﬂuid. The efﬁcacy of TFU was conﬁrmed in
SMMC-7721 xenografts in Balb/c athymic (nu?/nu?)
mice model. TFU treatment induced inhibition of SMMC-
7721 growth with few side effects. HPLC results showed
that high levels of TFU were still in liver 48 h after the end
of oral administration, implying that TFU preferentially
accumulated in liver with slow conversion to 5-FU by
enzymes. This led to a long-lasting concentration of 5-FU
in plasma. Further, a high level of 5-FU was found in
tumors with a relatively low level in lungs. These results
suggest that the metabolite of TFU was preferentially
converted or taken up by tumor cells. The distributions of
5-FU may contribute to its high anti-tumor activity and low
adverse reactions in vivo.
Conclusion These results demonstrate that TFU is a
promising prodrug of 5-FU for cancer treatment via sus-
tained release of 5-FU in liver.
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Introduction
Since Dushinsky et al. [1] synthesized 5-ﬂuorouracil (5-FU)
and discovered its anti-tumor activity in 1957, 5-FU has
been widely used in the treatment of various types of
cancer including stomach, intestine, liver, etc. [2, 3].
However, its half-life in plasma is very short (15–20 min),
thus continuous intravenous administration is needed to
maintain therapeutic concentrations [4, 5]. Moreover, the
clinical dose of 5-FU is very close to its toxic dosage
when given intravenously, resulting in signiﬁcant toxicity
to gastric and intestinal mucosa and bone marrow, making
long-lasting treatment difﬁcult [6, 7]. Hence, attempts
have been made to develop oral prodrugs with sustained
release of 5-FU at equal to or greater than its plasma
concentrations that could be obtained by intravenous
administration. For instance, S-1 was designed as an oral
anti-cancer agent that combines tegafur (FT), 5-chloro-
2,4-dihydroxypyridine (CDHP) and potassium oxonate
(Oxo) and that has an increased therapeutic index [2]. N
4-
pentoxycarbonyl-50-deoxy-5-ﬂuorocytidine (capecitabine)
is also an oral ﬂuoropyrimidine precursor that was
designed to undergo conversion in liver and tumor to
5-FU. Due to the high activity of thymidine phosphorylase
in tumors in converting capecitabine to 5-FU, capecita-
bine has been shown to have a superior therapeutic index
to 5-FU [8].
TFU, the metabolite of N1-acetyl-N3-o-toluyl-ﬂuoro-
uracil (atoﬂuding), is the prodrug of 5-FU (Fig. 1)[ 9–11].
Oral administration of TFU signiﬁcantly delayed the
growth of human gastric carcinoma xenografts in Balb/c
athymic (nu?/nu?)m i c e[ 9, 10]. TFU has been considered
to be a candidate ﬂuoropyrimidine derivative that could
replace the injectable 5-FU for cancer treatment [11–13].
Our previous studies showed that TFU signiﬁcantly sup-
pressed the growth of SGC-7901 and MKN-45 cells in
vitro in the presence of liver microsomal enzymes but only
weak inhibition without it. In the present study, we
examined the inhibitory effect of TFU on the proliferation
of human hepatocellular carcinoma cells. Further, the
metabolism of TFU in addition to the inhibitory action of
the drug was also investigated.
Materials and methods
Chemicals
N3-o-toluyl-ﬂuorouracil was synthesized by acylation of
5-FU with 2-methylbenzoyl chloride in pyridine at room
temperature as described previously [11]. TFU was dis-
solved in dimethylsulfoxide (DMSO) for the in vitro assay
and in 5% amylum for in vivo study.
Preparation of liver microsomal enzymes
Liver microsomal enzyme fraction was prepared from the
livers of male Sprague-Dawley rats which were intraper-
itoneally injected with phenobarbital [14]. The post-
mitochondrial fraction (S-9) was obtained from the liver
homogenate by centrifugation and then mixed with 0.1 M
phosphate buffer with 125 lM NADPH (nicotinamide
adenine dinucleotide phosphate). Two microliters of the
mixture was applied to each well of 96-well plates when
cells were incubated in the presence of liver microsomal
enzymes [9, 10].
Cell lines and cell culture
The human hepatocellular carcinoma cell lines SMMC-
7721 and PLC/PRF/5 were purchased from Shanghai Cell
Bank, the Institute of Cell Biology, China Academy of
Sciences (Shanghai, China). Cells were maintained in
RPMI-1640 supplemented with 10% (v/v) heat-inactivated
fetal bovine serum, 2 mM glutamine, and 10 mM HEPES
buffer at 37C in a humid atmosphere (5% CO2–95% air)
and were harvested by brief incubation in 0.02% (w/v)
EDTA in PBS (ICN, Aurora, OH, USA).
Inhibition of cell proliferation in vitro
Hepatocellular carcinoma cells (2.5 9 10
4 per well) seeded
in 96-well plates were exposed to different concentrations
of TFU (5–200 lgm l
-1) in the absence or presence of
liver microsomal enzymes for the indicated time. 5-FU
(20 lgm l
-1; Institute for Drug Control of China, Beijing)
was used as the positive control. To analyze the metabo-
lism of TFU in vitro, the cell culture supernatant ﬂuid was
collected from each well at the indicated time and the
concentrations of TFU and its metabolite 5-FU were ana-
lyzed by high-performance liquid chromatography (HPLC)
as described below. The wells were then washed with PBS
and cell viability was evaluated by the 3-[4,5-dimethyl-
thiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT,
Sigma, USA) assay as described elsewhere [15]. Triplicate
experiments with triplicate samples were performed.
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123Extraction of TFU and 5-FU from supernatant
ﬂuid of cell culture
One hundred microlitre of NaH2PO4 (0.5 M) and 2.5 ml
acetic ether were added to 500 ll of supernatant ﬂuid. The
mixture was vortexed for 3 min, then centrifuged
(3,000 rpm, 5 min). Two milliliters was transferred to a
clean tube thereafter and evaporated under nitrogen at
50C. The resulting residue was reconstituted with 200 ll
of mobile phase (acetonitrile–water, 50:50, v/v) for HPLC
measurement [11, 16].
HPLC conditions
The contents of TFU and 5-FU in cell culture supernatant
ﬂuid, plasma and tissue homogenates were measured at
258 nm by HPLC using an SPD-10Avp Shimadzu pump
and an LC-10Avp Shimadzu UV–vis detector. Samples
were chromatographed on a 4.6 9 250 mm reverse phase
stainless steel column packed with 5 lm particles (Venusil
XBP C-18, Agela, China) eluted with a mobile phase
consisting of 50:50 (v/v) mixture of acetonitrile and water
at a ﬂow rate of 1 ml min
-1 [11, 16]. Under these condi-
tions, the method of HPLC was established (Fig. 2). The
linearity of the method was evaluated by analyzing nine
calibration standards in triplicate over the nominal con-
centration range of 0.05–300 lgm l
-1 for TFU and 5-FU.
The correlation coefﬁcients obtained using 1/x
2 weighted
linear regressions were better than 0.9977 for TFU and
0.9985 for 5-FU (Fig. 2).
Inhibition of tumor growth in vivo
The in vivo efﬁcacy of TFU and distribution of drugs were
evaluated in SMMC-7721 xenografts mice model [9, 10].
Balb/c athymic (nu?/nu?) female mice, 4–6 weeks of age,
were purchased from Animal Center of China Academy of
Medical Sciences (Beijing, China). The animals were
housed under pathogen-free conditions. The research pro-
tocol was in accordance with the institutional guidelines of
Animal Care and Use Committee at Shandong University.
SMMC-7721 cells (1 9 10
7) were suspended in 100 llo f
Matrigel (Collaborative Biomedical, Bedford, USA) and
were injected subcutaneously into the right anterior ﬂank of
mice. After 7 days, when the tumor volume reached
approximately 0.1–0.2 cm
3, then 0, 25, 50, 100 mg kg
-1 of
TFU in 0.5 ml of 5% amylum were orally administered.
5-FU (25 mg kg
-1) was injected via the tail vein as a
positive control [3]. Drugs were administrated 6 days per
week for three consecutive weeks. Mice were killed 48 h
after the last dose. Tumor, liver and lung were harvested
and blood samples were collected from the postorbital
venous plexuse for drug analysis as described below. The
rate of tumor growth inhibition was deﬁned as a ratio to the
control (without TFU) tumor weight.
Sample extraction
The samples of liver, lung and tumor were weighed and
homogenized with 0.9% NaCl solution (1:3, w/w) in an ice
bath. Blood samples were centrifuged for 15 min
(4,000 rpm) in cold (4C) and then the plasma was
obtained. Two hundred microliters of NaH2PO4 (0.5 M)
and 2.5 ml of acetic ether were added to 500 llo ft h e
homogenate solution (plasma sample, 200 ll). The mixture
was vortexed for 3 min, then centrifuged (3,000 rpm,
5 min) [16, 17]. TFU and 5-FU extractions and HPLC
measurement were carried out as described above.
Statistical analysis
Data were described as the mean ± SD, and analyzed by
Student’s two-tailed t test. The limit of statistical signiﬁ-
cance was P\0.05. Statistical analysis was done with
SPSS/Win11.0 software (SPSS Inc., Chicago, IL).
Results
Anti-proliferative effects of TFU in vitro
Human hepatocellular carcinoma SMMC-7721 cells were
treated with TFU for up to 120 h and then subjected to the
MTT assay. As shown in Fig. 3 (top left) in the absence of
H2O, fast enzyme, slowly
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Fig. 1 Scheme for the
metabolism of atoﬂuding
to 5-FU via TFU
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123liver microsomal enzymes, incubation with TFU (5–
200 lgm l
-1) did not signiﬁcantly inhibit the growth of
SMMC-7721 cells, but signiﬁcance was seen with higher
concentrations and longer incubation times (100–
200 lgm l
-1, 96–120 h, the inhibition rates range from
16.5 to 20.4%, P\0.05 vs. relevant control).
The inhibitory effect of TFU on the proliferation of
SMMC-7721 cells was then examined in the presence of
liver microsomal enzymes. The inhibition rates were
greatly increased at all concentrations (5–200 lgm l
-1)
and incubation times (24–120 h), being 52–79% in
SMMC-7721 cells (Fig. 3, top right).
Similar proliferation proﬁles were observed for PLC/
PRF/5 cells exposed to TFU in the absence and presence of
liver microsomal enzymes (Fig. 3, bottom).
TFU sustained release of 5-FU in vitro
To analyze the metabolism of TFU mediated by liver
microsomal enzymes, the levels of TFU and its metabolite
5-FU in the medium from SMMC-7721 cell culture were
examined by HPLC. As shown in Fig. 4 (top left), TFU
was maintained at relative stable levels in all concentra-
tions and incubation times in the absence of liver
microsomal enzymes. However, a reduced level of TFU
was measured at doses of 100 and 200 lgm l
-1 at longer
incubation time (72–120 h, P\0.05 vs. 0 h control),
probably catalyzed by the cytosolic enzymes in cancer
cells [18]. Therefore, the much lower levels of its
metabolite 5-FU were detected in cell culture medium
(Fig. 4, top right).
The concentrations of TFU and 5-FU were then exam-
ined in the presence of liver microsomal enzymes. The
levels of TFU were gradually decreased (Fig. 4, bottom
left) and its metabolite 5-FU was increased slowly and
maintained the high levels for up to 120 h (bottom right).
These results implied that TFU was metabolized slowly
and the liver microsomal enzymes appeared to be impor-
tant for conversion of TFU to 5-FU.
Similar proﬁles of metabolism of TFU were observed in
PLC/PRF/5 cells exposed to TFU. Figure 5 shows the
concentrations of TFU and its metabolite 5-FU determined
by HPLC in cell culture medium from this cell line. In the
absence of liver microsomal enzymes, TFU was main-
tained at relative stable level (Fig. 5, top left) and the low
concentration of its metabolite 5-FU (top right) was found
in the cell culture medium. In contrast, the levels of TFU
were decreased gradually (Fig. 5, bottom left) and the
concentrations of its metabolite 5-FU were increased sig-
niﬁcantly in the presence of liver microsomal enzymes
(bottom right).
We also examined the concentrations of 5-FU, the
positive control in this experiment, in the medium from
SMMC-7721 culture after single treatment. The level of
Fig. 2 Examples of
chromatograms for TFU and
5-FU from control cell culture
medium (a), reference standard
(b) and medium from cell
culture with liver microsomal
enzymes (c). After incubation
with various concentrations of
TFU, the medium from cell
culture was extracted and the
drug content was determined by
HPLC on SPD-10Avp
Shimadzu pump and an
LC-10Avp Shimadzu UV–vis
detector as described in
‘‘Materials and methods’’.
The linearity of the method was
evaluated by analyzing nine
calibration standards in
triplicate over the nominal
concentration range of
0.05–300 lgm l
-1 for TFU and
5-FU. The correlation
coefﬁcients obtained using 1/x
2
weighted linear regressions
were better than 0.9977 for TFU
and 0.9985 for 5-FU. 1 DMSO,
2 5-FU, 3 TFU
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1235-FU was decreased rapidly within 120 min incubation,
indicating that 5-FU was degraded by the cytosolic
enzymes in cancer cells [18]. The degradation of 5-FU was
more pronounced in the presence of liver microsomal
enzymes than in the absence of enzymes (Fig. 6). Similar
result was found with PLC/PRF/5 cells (data not shown).
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123Efﬁcacy of TFU administration in mice
We evaluated the efﬁcacy of TFU in hepatocellular carci-
noma xenografts in Balb/c athymic (nu?/nu?) mice. As
shown in Table 1, the growth of SMMC-7721 tumor was
signiﬁcantly delayed after 3 weeks of oral administration.
At doses of 25, 50 and 100 mg kg
-1 of TFU, the inhibition
rates were 38.9, 51.9 and 60.8%. Suppression of SMMC-
7721 tumor growth was dose dependent (25 mg kg
-1,
P\0.05 vs. untreated group; 50 and 100 mg kg
-1,
P\0.01 vs. untreated group). TFU treatment was gener-
ally well tolerated by mice with less than 20% reduction in
body weight (50 and 100 mg kg
-1, P[0.05 vs. untreated
group). In contrast, a signiﬁcant body weight loss was
observed (25.9%, P\0.01 vs. untreated group) and three
mice died during the continuous administration of 5-FU via
the tail vein (Table 1).
Distributions of 5-FU and TFU in mice
The distributions of TFU and its metabolite 5-FU in
plasma, liver, lung and tumor were measured by HPLC. As
expected, high levels of TFU were detected in liver, while
TFU was not detected in plasma, lung and tumor, indi-
cating that the drug was preferentially accumulated and
metabolized in liver (Table 2). We analyzed the concen-
tration of 5-FU in the same samples. The plasma 5-FU
remained relatively at stable levels (13.52–15.82 ng ml
-1)
although the drug administration ended 48 h before. 5-FU
content was high in liver, suggesting that 5-FU accumu-
lated after TFU degradation. Importantly, higher content of
5-FU was found in SMMC-7721 xenografts and relatively
lower levels were measured in lungs (Table 2), indicating
that the tumor was the main site of action of 5-FU. In
contrast, 5-FU was not detected in plasma, liver, lung or
incubation time (h)
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123tumor in animals at this time point (48 h after the last dose
of 5-FU) when 5-FU was intravenously given (Table 2).
Discussion
N3-o-toluyl-ﬂuorouracil is the metabolite of N1-acetyl-N3-
o-toluyl-ﬂuorouracil (atoﬂuding) [19]. Previously, atoﬂud-
ing had been proven effective against many types of tumors
including intestinal, gastric and esophageal carcinoma in
phase III clinical trials [19]. However, its development was
discontinued due to the instability of the preparation
[9, 10]. Further studies indicated that the acetyl group is
prone hydrolysis into TFU rapidly by ﬂuorine at the C5
position (Fig. 1), impairing quality control for the prepa-
ration. In contrast, TFU is stable and therefore a signiﬁcant
level of TFU was detected in serum rather than atoﬂuding
itself in clinical trials [19]. Our previous studies also
showed that its metabolite 5-FU was detected at 50 h after
single oral atoﬂuding [9, 10, 20]. Thereafter, we presumed
that TFU would be the prodrug of 5-FU. Direct application
of TFU may be superior to atoﬂuding.
TFU conversion and sustained release of 5-FU are very
important for its activity evaluation. Many derivatives of
ﬂuoropyrimidine are metabolized primarily in the liver by
microsomal enzymes and then release their metabolite
5-FU into circulation [21, 22]. For instance, the bio-acti-
vation of capecitabine to 5-FU is considered to take place
in three steps by different enzymes in the liver including
carboxylesterase, cytidine deaminase and thymidine phos-
phorylase [23]. The pharmacokinetic studies in patients
showed that the highest plasma level of 5-FU was detected
1 h after administration and maintained an active level for
1.5 h [23]. In the current study, we mimicked the catalytic
procedure of TFU in vitro and found that TFU maintained
high concentrations in the absence of liver microsomal
enzymes. However, a slight reduction in TFU was observed
with long incubation times. The cytosolic enzymes in
tumors may also be involved in metabolism of the ﬂuoro-
pyrimidine derivatives [8, 18, 23]. Therefore, we presumed
Table 1 The inhibitory effects of TFU on SMMC-7721 xenograft in Balb/c athymic (nu?/nu?) mice
Dosage
(mg kg
-1)
Mice
survived (n)
Body weight
a
(g; mean ± SD)
Tumor weight
b
(g; mean ± SD)
Tumor growth
inhibition (%)
TFU
0 10 22.32 ± 2.33 3.37 ± 0.54 –
25 10 22.81 ± 1.84 2.05 ± 0.69* 38.9
50 10 20.74 ± 1.63 1.62 ± 0.61** 51.9
100 10 20.13 ± 2.12 1.32 ± 0.62** 60.8
5-FU
20 7 16.51 ± 2.23 1.53 ± 1.03** 54.5
Established tumors (0.1–0.2 cm
3) were treated orally with TFU 7 days post-SMMC-7721 implant as described in ‘‘Materials and methods’’
* P\0.05, ** P\0.01 versus untreated group
a Body weight was measured after ﬁnishing drug administration
b Tumor measurements were made after mice killed
Table 2 The distribution of 5-FU and TFU in different tissues and SMMC-7721 xenografts in Balb/c athymic (nu?/nu?) mice (n = 10)
Dosage (mg kg
-1) Content of TFU (lgg
-1) Content of 5-FU (lgg
-1)
Plasma (ng ml
-1) Lung Liver Tumor Plasma (ng ml
-1) Lung Liver Tumor
TFU
0 N d N d N dN d N d N dN d N d
25 Nd Nd 10.21 ± 1.38 Nd 13.52 ± 0.36 42.08 ± 5.17 168.24 ± 20.11 154.89 ± 19.28
50 Nd Nd 36.54 ± 3.54 Nd 14.87 ± 0.53 53.12 ± 6.33 214.93 ± 27.59 197.81 ± 15.36
100 Nd Nd 59.63 ± 4.87 Nd 15.82 ± 0.43 68.34 ± 9.35 280.30 ± 37.21 264.78 ± 20.73
5-FU
25 – – – – Nd Nd Nd Nd
TFU was orally given for three consecutive weeks. The measurement of TFU and 5-FU was performed 48 h after the last dose. 5-FU was injected
via tail vein as a positive control
Nd concentration of drug was not detectable
Cancer Chemother Pharmacol (2010) 66:11–19 17
123that TFU was also degraded by the cytosolic enzymes in
medium of cell culture in the absence of liver microsomal
enzymes. In the presence of liver microsomal enzymes, the
concentrations of TFU were gradually reduced and con-
sequently the levels of 5-FU were increased, indicating that
the sustained release of 5-FU was mainly metabolized by
liver microsomal enzymes. The conversion of TFU and
sustained release of 5-FU were conﬁrmed by the mea-
surement of plasma drug concentrations in mice bearing
SMMC-7721 tumors. The concentration of 5-FU was
detected in plasma 48 h after ﬁnishing oral administration,
indicating that the long-lasting plasma 5-FU was released
from TFU. The maintenance of the long-lasting plasma
5-FU is probably the main reason for its high anti-tumor
activity in vivo [9].
The distribution and accumulation of 5-FU in tumors are
also very important for the evaluation of anti-tumor activity
of TFU. In this study, we examined the levels of drugs in
plasma, liver, lung and tumor. High levels of TFU and its
metabolite 5-FU were detected in liver, indicating that TFU
preferentially accumulated in liver and was slowly
metabolized to 5-FU [9, 10]. Therefore, prolonged levels of
5-FU were detected in plasma. Many studies have shown
that prolonged continuous steady-state concentrations of
5-FU are superior to intermittent bolus injections in
patients receiving adjuvant therapy [9]. The administration
of intermittent bolus injections caused many serious tox-
icities [9]. Therefore, various prodrugs of 5-FU which
continuously release 5-FU have been developed including
S-1, capecitabine and TFU [2, 9, 23]. Importantly, 5-FU
levels appear to be high in tumors and relatively low in
lungs, indicating that the metabolite of TFU is preferen-
tially converted or taken up by tumor cells. Tumor was the
main site of action of 5-FU. These distributions of the
metabolite 5-FU may contribute to the high therapeutic
index of TFU in vivo.
The bio-activation of TFU to 5-FU has remained
unknown. Because liver microsomal enzymes contain
various forms of reductase and oxygenase [21, 22], the
conversion of TFU may associate with the hydrolytic
activity in liver microsomal enzymes [9]. Liver micro-
somal enzymes are the NADPH-dependent reductase [24].
The activity of reductase is initiated by donating electrons
from NADPH consumption [14, 25]. By the bio-transfor-
mation pathways in liver, 5-FU is slowly released into
blood and then preferentially distributed in tumor. Due to
the high activity of the many 5-FU-associated enzymes in
tumor tissues, i.e., dihydropyrimidine dehydrogenase, thy-
midylate synthase, orotate phosphoribosyl transferase, and
thymidine phosphorylase, 5-FU is preferentially accumu-
lated and converted to its active form in tumor cells [2, 8,
9]. In addition, some of the cytosolic enzymes including
cytidine deaminase have been found in high levels in
tumors [23, 26]. These enzymes are responsible for the
intracellular activation of the ﬂuoropyrimidine from the
intermediate metabolite to the active form 5-FU [23, 26,
27]. We presume that these cytosolic enzymes are also
involved in converting the intermediate metabolite of TFU
to 5-FU in tumors. A high level of 5-FU was found in
tumors. The bio-transformation pathways of TFU to 5-FU
and the distributions of the intermediate metabolites need
to be further investigated.
In conclusion, treatment of TFU in the presence of liver
microsomal enzymes and oral administration of TFU in
mice induced inhibitory effects on proliferation of hepa-
tocellular carcinoma cells and tumors. Measurement of
drug concentrations revealed that the inhibitory effect of
TFU was associated with sustained release of 5-FU from
TFU degraded by liver microsomal enzymes. The results
presented here provide strong support for the effective
development of TFU as a promising ﬂuoropyrimidine
derivative for cancer treatments.
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